Support the OCRF’s Early Detection Research Appeal

The OCRF is calling for urgent donations to help fund the next phase of an exciting research project at the Hudson Institute of Medical Research, focused on identifying early-stage ovarian cancer.

Called the Active Ratio Test, this project has the potential to revolutionise the future of women’s health, by providing a simple, accessible, and reliable screening test that can be included as part of a standard health check-up. Learn more about the Active Ratio Test here.


Why the OCRF needs your support

This year, the OCRF has received an unprecedented number of high-quality grant applications. Each of these has the potential to break new ground, add to our current understanding, and get us progressively closer to finding an early detection test.

We are calling for $45,000 which will partially fund the researchers behind the Active Ratio Test project for another year. Now at the stage of prospective clinical trials, funding is urgently needed to continue the momentum of the work done so far. Donate Now



By raising funds to support the innovative research that will identify an early detection test, the OCRF is committed to creating a world where every woman, everywhere can live free from the threat of ovarian cancer.

Because without an early detection test, five-year survival rates are as low as 30%. Just as worryingly, close to 90% of women diagnosed with ovarian cancer experience recurrence within 18 months.


Leane’s story

At her usual gynaecological check-up in April last year, Leane mentioned several symptoms she had noticed—cramps, bloating, and needing to urinate more frequently. No one would have guessed that Leane had stage 3C ovarian cancer—it was a shock discovery following an ultrasound ordered to confirm a diagnosis of menopause.

“In hindsight, I think about how I could have done something sooner. I think about how I could have known. But that’s the worrying part—without an early detection test, we don’t have a reliable way of knowing early.”

Despite initial positive results following immediate surgery, Leane is currently receiving treatment due to recurrence.


A changing research landscape

Why is an early detection test proving so elusive? It’s the question that women, loved ones and researchers alike grapple with, and something that we at the OCRF are determined to resolve.

Despite the difficulties involved with studying a disease which has over 20 subtypes which each occur differently, with unique rates of spread and treatment efficacy, ovarian cancer research has made some significant strides in the past decade. Thanks to this ongoing work, researchers are now confident of where they need to hone their research efforts, driving us closer to finding the solution.


The OCRF-funded project, ‘Measuring the CXCL10 Active Ratio‘ is currently investigating a protein biomarker capable of providing an early stage indicator of ovarian cancer. This study has made exciting progress and is now at the stage of prospective trial, which will be conducted with women who are genetically at risk of developing ovarian cancer.

The next challenges involve refining the Active Ratio Test to ensure that it works at the highest degree of septicity and sensitivity—minimising the chances of false positives, while ensuring no malignant tumours go undetected. The goal is to continue testing and improving this method, until the Active Ratio Test forms a part of a woman’s standard health check-up and screening schedule.

OCRF-funded researcher Dr Maree Bilandzic, Senior Research Fellow at Hudson Institute of Medical Research, discusses this exciting project and why an early detection test is so crucial.


Your donation makes all the difference

This is an exciting time for ovarian cancer research, and this progress would not have been possible without years of ongoing funding from the OCRF.

Please make a tax-deductible donation to support the OCRF’s goal of raising the $45,000 required to continue this life-saving research.

Research is the only way that we will find an early detection test for ovarian cancer—the key to saving Australian women’s lives and creating a future free from the fear of this insidious disease. And it is only thanks to ongoing support that we can continue to fund this life-saving work.

Please give generously to support this vital research.